AKTX — Akari Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $7.84m
- $4.00m
Annual cashflow statement for Akari Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.1 | -17.1 | -17.4 | -17.7 | -10 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.08 | 0.178 | 0.557 | -4.58 | -5.56 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.09 | -0.056 | -1.98 | 0.822 | -0.866 |
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -12.9 | -17 | -18.8 | -21.5 | -16.4 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 0 | — | — | — | — |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 12.6 | 25.1 | 14.3 | 25.3 | 7.02 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.236 | 8.32 | -4.69 | 3.89 | -9.4 |